<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="78891">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01853046</url>
  </required_header>
  <id_info>
    <org_study_id>16653</org_study_id>
    <nct_id>NCT01853046</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment</brief_title>
  <official_title>A Phase I, Multi-center, Non-randomized, Open Label, Parallel-group Study Evaluating the Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer Subjects With Severe Renal Impairment Compared to a Control Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To characterize the pharmacokinetics and safety of regorafenib in cancer subjects with
      severe renal impairment when compared to the Control group (cancer subjects with normal or
      mildly impaired renal function)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>AUC(0-tlast) [area under the concentration-time curve after single dose from time zero to the last data point &gt;LLOQ (lower limit of quantification)] for regorafenib and its pharmacologically active metabolites M-2 and M-5</measure>
    <time_frame>Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>based on non-compartmental PK evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-24)md [Area under the concentration-time curve after multiple dose from time zero to 24 hours for regorafenib and its pharmacologically active metabolites M-2 and M-5</measure>
    <time_frame>Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>based on population PK model evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AE,ur(0-24) (amount of drug excreted via urine during the collection interval 0-24 hours post administration) for metabolites M-7 and M-8</measure>
    <time_frame>Days 1-2: 0-10 and 10-24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response assessment for measurable lesions according to RECIST, v1.1 (Response Evaluation Criteria in Solid Tumors)</measure>
    <time_frame>Up to 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of bone metastases by scintigraphy (bone scan)</measure>
    <time_frame>Up to 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (area under the plasma concentration vs. time curve from zero to infinity after single (first) dose) for regorafenib and its pharmacologically active metabolites M-2 and M-5</measure>
    <time_frame>Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>based on non-compartmental PK evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-24) (AUC from time zero to 24 hours p.a. after first-dose administration) for regorafenib and its pharmacologically active metabolites M-2 and M-5</measure>
    <time_frame>Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>based on non-compartmental PK evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum drug concentration in plasma after first dose administration) for regorafenib and its pharmacologically active metabolites M-2 and M-5</measure>
    <time_frame>Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>based on non-compartmental PK evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax (time to reach maximum drug concentration in plasma after single (first) dose) for regorafenib and its pharmacologically active metabolites M-2 and M-5</measure>
    <time_frame>Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>based on non-compartmental PK evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tlast (time of last data point &gt;LLOQ) for regorafenib and its pharmacologically active metabolites M-2 and M-5</measure>
    <time_frame>Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>based on non-compartmental PK evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 (half-life associated with the terminal slope) for regorafenib and its pharmacologically active metabolites M-2 and M-5</measure>
    <time_frame>Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>based on non-compartmental PK evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F (total body clearance of drug after extravascular administration) for regorafenib and its pharmacologically active metabolites M-2 and M-5</measure>
    <time_frame>Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>based on non-compartmental PK evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F (apparent volume of distribution during terminal phase after single oral administration) for regorafenib and its pharmacologically active metabolites M-2 and M-5</measure>
    <time_frame>Days 1-5: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, 24, 48 and 96 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>based on non-compartmental PK evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-24)md ((AUC(0-24) after multiple-dose administration) for regorafenib and its pharmacologically active metabolites M-2 and M-5</measure>
    <time_frame>Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, and 24 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>based on non-compartmental PK evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-24)md ((AUC(0-24) after multiple-dose administration) for regorafenib and its pharmacologically active metabolites M-2 and M-5</measure>
    <time_frame>Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, and 24 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>based on population PK model evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,md (Cmax after multiple-dose administration) for regorafenib and its pharmacologically active metabolites M-2 and M-5</measure>
    <time_frame>Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, and 24 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>based on non-compartmental PK evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-tlast)md (AUC(0-tlast) after multiple-dose administration) for regorafenib and its pharmacologically active metabolites M-2 and M-5</measure>
    <time_frame>Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, and 24 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>based on non-compartmental PK evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-tlast)md (AUC(0-tlast) after multiple-dose administration) for regorafenib and its pharmacologically active metabolites M-2 and M-5</measure>
    <time_frame>Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, and 24 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>based on population PK model evaluation and on actual individual dosing schedule</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-tlast)md (AUC(0-tlast) after multiple-dose administration) for regorafenib and its pharmacologically active metabolites M-2 and M-5</measure>
    <time_frame>Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, and 24 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>based on population PK model evaluation and on the nominal dosing schedule</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax,md (time to reach maximum drug concentration in plasma after multiple-dose administration) for regorafenib and its pharmacologically active metabolites M-2 and M-5</measure>
    <time_frame>Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, and 24 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>based on non-compartmental PK evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tlast,md (tlast after multiple-dose administration) for regorafenib and its pharmacologically active metabolites M-2 and M-5</measure>
    <time_frame>Days 21-25: Pre-dose, 0.5, 1, 2, 4, 6, 8, 10, and 24 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>based on non-compartmental PK evaluation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Regorafenib (severe impairment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cancer subjects with severe renal impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regorafenib (normal impairment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cancer subjects with normal or mildly impaired renal function</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib (Stivarga, BAY73-4506)</intervention_name>
    <description>Regorafenib 160 mg o.d. will be administered as a single dose on Day 1 of Stage 1 (at least 6 days) followed by multiple dosing in an intermittent administration schedule (3 week-on/1 week-off) over 2 cycles in Stage 2 (56 days, cycle defined as 28 days).</description>
    <arm_group_label>Regorafenib (severe impairment)</arm_group_label>
    <arm_group_label>Regorafenib (normal impairment)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with histologically confirmed, locally advanced or metastatic, refractory
             solid tumors who are not candidates for standard therapy

          -  Male or female subject ≥ 18 years of age

          -  Women of childbearing potential must have a negative urine pregnancy test performed
             within 7 days before start of study treatment

          -  Life expectancy at least 8 weeks

          -  Adequate bone marrow, and liver function as assessed by the following laboratory
             requirements conducted within 7 days of starting the study treatment

          -  For subjects with NORMAL OR MILDLY IMPAIRED RENAL FUNCTION (Control group); to be
             tested within 7 days of starting the study treatment:

               -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2

               -  Estimated creatinine clearance (CLcr) ≥ 60 mL/min as calculated using the
                  Cockcroft-Gault equation

          -  For subjects with SEVERELY IMPAIRED renal function; to be tested within 7 days of
             starting the study treatment:

               -  CLcr 15-29 mL/min as calculated using the Cockcroft-Gault equation

        Exclusion Criteria:

          -  Symptomatic metastatic brain or meningeal tumors

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             before start of study medication

          -  History of organ allograft

          -  Non-healing wound, skin ulcer, or bone fracture

          -  Pheochromocytoma

          -  Uncontrolled concurrent medical illness including uncontrolled hypertension

          -  History of cardiac disease

          -  Pleural effusion or ascites that causes respiratory compromise

          -  Interstitial lung disease with ongoing signs and symptoms at the time of screening

          -  Arterial or venous thrombotic or embolic events such as cerebrovascular accident
             (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism
             within 6 months before the start of study medication

          -  Subjects with evidence or history of bleeding diathesis; any hemorrhage or bleeding
             event NCI-CTCAE Grade ≥ 3 or higher within 4 weeks of start of investigational
             treatment

          -  Dehydration NCI-CTCAEversion 4.0 Grade ≥ 1

          -  Unresolved toxicity higher than NCI-CTCAE version 4.0 Grade 1 attributed to any prior
             therapy/procedure (excluding alopecia or anemia or grade 2 neuropathy that is not
             reversible due to oxaliplatin)

          -  Seizure disorder requiring anticonvulsant therapy (such as steroids or
             anti-epileptics)

          -  For subjects with SEVERELY IMPAIRED renal function:

               -  Renal failure requiring hemo- or peritoneal dialysis

               -  Acute renal failure

               -  Acute nephritis

               -  Nephrotic syndrome
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <email>clinical-trials-contact@bayerhealthcare.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>For trial location information (Phone Menu Options '3' or '4')</last_name>
    <phone>(+)1-888-84 22937</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 16, 2014</lastchanged_date>
  <firstreceived_date>May 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Regorafenib</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>safety</keyword>
  <keyword>severe renal impairment</keyword>
  <keyword>Solid tumors</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
